- Home
- INR vs BSX Comparison
INR vs BSX Comparison
Compare INR & BSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INR
- BSX
- Stock Information
- Founded
- INR 2017
- BSX 1979
- Country
- INR United States
- BSX United States
- Employees
- INR N/A
- BSX N/A
- Industry
- INR
- BSX Medical/Dental Instruments
- Sector
- INR
- BSX Health Care
- Exchange
- INR NYSE
- BSX Nasdaq
- Market Cap
- INR N/A
- BSX 138.4B
- IPO Year
- INR 2025
- BSX 1992
- Fundamental
- Price
- INR $16.03
- BSX $102.73
- Analyst Decision
- INR Strong Buy
- BSX Strong Buy
- Analyst Count
- INR 7
- BSX 23
- Target Price
- INR $27.43
- BSX $110.57
- AVG Volume (30 Days)
- INR 314.7K
- BSX 10.3M
- Earning Date
- INR 01-01-0001
- BSX 04-23-2025
- Dividend Yield
- INR N/A
- BSX N/A
- EPS Growth
- INR N/A
- BSX 15.23
- EPS
- INR N/A
- BSX 1.37
- Revenue
- INR $259,022,000.00
- BSX $17,554,000,000.00
- Revenue This Year
- INR $49.25
- BSX $15.77
- Revenue Next Year
- INR $17.14
- BSX $10.33
- P/E Ratio
- INR $19.76
- BSX $75.05
- Revenue Growth
- INR 60.16
- BSX 19.36
- 52 Week Low
- INR $13.64
- BSX $70.97
- 52 Week High
- INR $23.00
- BSX $107.17
- Technical
- Relative Strength Index (RSI)
- INR N/A
- BSX 61.22
- Support Level
- INR N/A
- BSX $92.70
- Resistance Level
- INR N/A
- BSX $102.37
- Average True Range (ATR)
- INR 0.00
- BSX 2.95
- MACD
- INR 0.00
- BSX 1.17
- Stochastic Oscillator
- INR 0.00
- BSX 97.14
About BSX Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.